Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells.
OBJECTIVE
To investigate antiproliferative and radiosensitizing effects of caffeic acid phenethyl ester (CAPE) on medulloblastoma (MB) Daoy cells.


METHODS
Daoy cells were treated with CAPE in different concentrations and assessed for cell viability, apoptosis, cell cycles, cyclin B1 expressions, radiosensitization and chemosensitization. Human astroglia SVGp12 cells were treated with CAPE to present the possible protection or complication effects in normal tissues.


RESULTS
CAPE inhibited the growth of Daoy cells in a time- and concentration-dependent manner in MTT and Trypan blue exclusion assays. Flow cytometry revealed that CAPE significantly decreased G2/M fraction, and increased the S phase fraction. Western blot demonstrated a down-regulated cyclin B1 protein expression. Pretreatment with CAPE markedly decreased the viability of irradiated Daoy cells. The sensitizer enhancement ratios (SERs) were increased in CAPE-treated Daoy cells. CAPE in doxorubicin and cisplatin did not show chemosensitizing effect.


CONCLUSIONS
These findings demonstrate the antiproliferative and radiosensitizing effects of CAPE for Daoy cells, which might bring improvement to the treatment of MB. For clinical application, in vivo models are expected.
Lin
Yi-Hsien
YH
Institute of Traditional Medicine, National Yang-Ming University, 155. Sec. 2, Li-Nong St., Peitou, Taipei, 112, Taiwan.
Chiu
Jen-Hwey
JH
Tseng
Wen-Ser
WS
Wong
Tai-Tong
TT
Chiou
Shih-Hwa
SH
Yen
Sang-Hue
SH
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D001253:Astrocytes / Q000187:drug effects; D015153:Blotting, Western; D002109:Caffeic Acids / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000494:pharmacology; D053938:DNA Fragmentation; D004317:Doxorubicin / Q000494:pharmacology; D004357:Drug Synergism; D006801:Humans; D020287:In Situ Nick-End Labeling; D008527:Medulloblastoma / Q000188:drug therapy* / Q000473:pathology; D010626:Phenylethyl Alcohol / Q000031:analogs & derivatives* / Q000494:pharmacology; D011838:Radiation-Sensitizing Agents; D014410:Tumor Stem Cell Assay
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D002109:Caffeic Acids; D011838:Radiation-Sensitizing Agents; D004317:Doxorubicin; C055494:caffeic acid phenethyl ester; D010626:Phenylethyl Alcohol; D002945:Cisplatin